Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Medicus Pharma Ltd. - Common Stock
(NQ:
MDCX
)
1.210
-0.180 (-12.95%)
Delayed Quote
Updated: 11:46 AM EST, Nov 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Medicus Pharma Ltd. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Medicus Pharma Regains Compliance with Nasdaq Minimum Equity Requirement for Continued Listing
Today 7:30 EST
Nasdaq Confirmation follows CEO-Led $4.25 million in Equity Financings and $10.5 million debt exchange to satisfy the alternative minimum shareholders’ equity standard
From
Medicus Pharma Ltd
Via
GlobeNewswire
Medicus Pharma Announces Closing of $4.25 Million CEO-Led Equity Financings and $10.5 Million Debt Exchange
November 16, 2026
From
Medicus Pharma Ltd
Via
GlobeNewswire
Medicus Pharma (MDCX) Q3 2026 Earnings Call Transcript
↗
November 09, 2026
A SkinJect SPAC plan and melanoma focus mark the next phase.
Via
The Motley Fool
Topics
Earnings
Medicus Pharma to Highlight Rationale for CD228V Co-Development and License Agreement
November 09, 2026
Capital efficiency strategy prioritizes CD228V development while seeking separate public listing for SkinJect ® and partners to advance Teverelix®
From
Medicus Pharma Ltd
Via
ACCESS Newswire
Medicus Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
November 06, 2026
Company Highlights CD228V as its Principal Development Priority, Proposed SPAC Business Combination at ~ $135 Million Valuation for SkinJect® and Teverelix® as a Partner-Ready Program
From
Medicus Pharma Ltd
Via
ACCESS Newswire
Medicus Pharma to Present at BIO-Europe 2026
November 05, 2026
Medicus Chief Medical Officer will Highlight Company’s Focus on Precision Oncology, Anchored by CD228V targeted ADC and Partner Ready Therapeutic Programs
From
Medicus Pharma Ltd
Via
GlobeNewswire
Medicus Pharma Announces Proposed SkinJect® Business Combination and Concurrent Financing
November 04, 2026
The proposed transaction would value SkinJect® at ~$135 million and include financing at closing to support the SKNJCT-005 NDA-enabling study in Gorlin Syndrome patients
From
Medicus Pharma Ltd
Via
GlobeNewswire
Medicus Pharma to Present at BioFuture and Global Biotechnology Summit
October 27, 2026
Company’s Executive Chairman and CEO to Speak on Cancer Therapeutics Spotlight Panel at BioFuture in NYC and Deliver Keynote Address at Global Biotechnology Summit in Abu Dhabi
From
Medicus Pharma Ltd
Via
GlobeNewswire
Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
October 26, 2026
Nasdaq closes the minimum bid price matter confirming that the Company has regained compliance
From
Medicus Pharma Ltd
Via
GlobeNewswire
Friday's after hours session: top gainers and losers
↗
October 09, 2026
Via
Chartmill
These stocks are moving in today's pre-market session
↗
October 09, 2026
Via
Chartmill
Top stock movements in today's session.
↗
October 08, 2026
Via
Chartmill
Let's take a look at the stocks that are in motion in today's session.
↗
October 08, 2026
Via
Chartmill
Traders are paying attention to the gapping stocks in Thursday's session.
↗
October 08, 2026
Via
Chartmill
Thursday's pre-market session: top gainers and losers
↗
October 08, 2026
Via
Chartmill
Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
October 08, 2026
Advancing Precision Oncology and Partner-Ready Therapeutic Programs Through Capital-Efficient Development
From
Medicus Pharma Ltd
Via
GlobeNewswire
What's going on in today's after hours session
↗
October 07, 2026
Via
Chartmill
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
September 29, 2026
Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company’s capital-efficient development strategy
From
Medicus Pharma Ltd
Via
GlobeNewswire
Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
September 21, 2026
Decision advances Company’s previously announced capital-efficient development strategy by concentrating resources on FDA-authorized, SKNJCT-005, NDA-enabling, Registrational Phase 2b Study in Gorlin...
From
Medicus Pharma Ltd
Via
GlobeNewswire
Unusual volume stocks are being observed in Thursday's session.
↗
September 10, 2026
Via
Chartmill
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
September 10, 2026
CSR provides a clinical foundation for the Company’s recently announced capital-efficient focus on FDA-authorized Gorlin Syndrome NDA-enabling development program while supporting partnership...
From
Medicus Pharma Ltd
Via
GlobeNewswire
Unusual volume stocks in Tuesday's session
↗
September 08, 2026
Via
Chartmill
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
September 08, 2026
Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect® and Teverelix® indications
From
Medicus Pharma Ltd
Via
GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
September 03, 2026
Via
Chartmill
Check out the stocks that are attracting the most attention and driving market activity.
↗
September 03, 2026
Via
Chartmill
Thursday's session: top gainers and losers
↗
September 03, 2026
Via
Chartmill
Gapping stocks in Thursday's session
↗
September 03, 2026
Via
Chartmill
Wondering what's happening in today's pre-market session?
↗
September 03, 2026
Via
Chartmill
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026
From
Medicus Pharma Ltd
Via
ACCESS Newswire
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
August 03, 2026
Dr. Mehmud’s appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev
From
Medicus Pharma Ltd
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit